Results of the NCPE assessment due next week.
The NCPE do not believe that rivaroxaban is cost-effective for this indication at the submitted price.
We believe that at the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion.